Efficacy and resistance

The clinical evidence to support DESCOVY^®▼ (emtricitabine / tenofovir alafenamide) in combination with other antiretroviral agents for the treatment of HIV is based on studies conducted with FTC and TAF when given with boosted EVG as the fixed-dose combination tablet E/C/F/TAF,^1-5 and data from a phase 3 trial in virologically suppressed adults with HIV infection. ^6-8